For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy.
Bladder cancer
Bladder preservation
Complete response
Neoadjuvant chemotherapy
Journal
European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661
Informations de publication
Date de publication:
05 May 2023
05 May 2023
Historique:
received:
29
10
2022
revised:
22
01
2023
accepted:
21
04
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
7
5
2023
Statut:
aheadofprint
Résumé
Given the morbidity associated with radical cystectomy (RC) and the significant survival benefit for patients who experience tumor downstaging after neoadjuvant chemotherapy (NAC), there is growing interest in bladder preservation strategies for select patients who have a complete response (CR) to NAC. In this mini-review we discuss the concept of avoiding RC as an alternative option for patients who experience a clinical CR following NAC. Several studies support this concept, with comparable long-term survival outcomes observed for patients with cT0 disease after NAC and patients undergoing RC. However, the definitive approach and the optimal surveillance strategy for patients with a clinical CR who choose bladder preservation are lacking. A dynamic response-driven bladder preservation strategy is a highly anticipated option for patients and is needed to avoid debilitating overtreatment. PATIENT SUMMARY: For selected patients with bladder cancer who experience a complete response to chemotherapy before any surgery, close follow-up might be an alternative option to surgical removal of the bladder without compromising cancer control.
Identifiants
pubmed: 37150628
pii: S2405-4569(23)00106-2
doi: 10.1016/j.euf.2023.04.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.